CPT-11 Clinical Trials

1 actively recruiting trial

Also known as: Irinotecan

Pipeline

Phase 3: 1

Top Sponsors

Sun Yat-sen University1

Indications

Intestinal Neoplasms1
Digestive System Neoplasms1
Gastrointestinal Neoplasms1
Neoplasm Metastasis1
Colorectal Neoplasms1

Other1 trial

A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.